Conmed/$CNMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Conmed
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Ticker
$CNMD
Sector
Primary listing
NYSE
Employees
3,900
Headquarters
Website
Conmed Metrics
BasicAdvanced
$1.6B
14.26
$3.54
1.21
$0.80
1.58%
Price and volume
Market cap
$1.6B
Beta
1.21
52-week high
$75.20
52-week low
$46.00
Average daily volume
411K
Dividend rate
$0.80
Financial strength
Current ratio
2.231
Quick ratio
0.909
Long term debt to equity
87.859
Total debt to equity
87.93
Dividend payout ratio (TTM)
22.42%
Interest coverage (TTM)
4.34%
Profitability
EBITDA (TTM)
220.069
Gross margin (TTM)
55.93%
Net profit margin (TTM)
8.31%
Operating margin (TTM)
11.85%
Effective tax rate (TTM)
19.97%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
4.03%
Return on equity (TTM)
11.69%
Valuation
Price to earnings (TTM)
14.259
Price to revenue (TTM)
1.178
Price to book
1.6
Price to tangible book (TTM)
-3.57
Price to free cash flow (TTM)
10.541
Free cash flow yield (TTM)
9.49%
Free cash flow per share (TTM)
4.789
Dividend yield (TTM)
1.58%
Forward dividend yield
1.58%
Growth
Revenue change (TTM)
3.94%
Earnings per share change (TTM)
12.85%
3-year revenue growth (CAGR)
8.36%
10-year revenue growth (CAGR)
6.17%
3-year earnings per share growth (CAGR)
-2.93%
10-year earnings per share growth (CAGR)
13.82%
What the Analysts think about Conmed
Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Bulls say / Bears say
Conmed’s Q2 2025 sales increased 3.1% year-over-year to $342.3 million, led by 2.8% growth in U.S. revenue and 3.4% growth internationally, showing strong overall revenue momentum. (Business Wire)
Adjusted diluted EPS rose 17.3% to $1.15 in Q2 2025, marking the third consecutive quarter of adjusted earnings growth, with gross margin improving by 120 basis points to 56.5%. (Business Wire)
After the Q2 results, management raised their full-year 2025 revenue forecast to $1.356 billion–$1.378 billion and adjusted EPS guidance to $4.40–$4.55, up from $4.31–$4.46, expressing confidence in offsetting currency headwinds. (Business Wire)
GAAP diluted EPS dropped to $0.69 in Q2 2025 from $0.96 the previous year, revealing the effects of tariff-related costs and special items on reported profits. (Business Wire)
The company anticipates a negative EPS impact of roughly $0.09 in the second half of 2025 due to newly announced tariffs, highlighting ongoing pressure on margins from external trade policies. (Business Wire)
Management is still working to resolve supply chain challenges, having hired a consulting firm to improve procurement and production planning, with full stabilization not expected before year-end. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Conmed Financial Performance
Revenues and expenses
Conmed Earnings Performance
Company profitability
Conmed News
AllArticlesVideos
CONMED Corporation Announces Quarterly Cash Dividend
Business Wire1 month ago
Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc.
Business Wire2 months ago
CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct3
Conmed
DividendPayment
$0.20Per share
FAQs
What’s the current market cap for Conmed stock?
Conmed (CNMD) has a market cap of $1.6B as of September 18, 2025.
What is the P/E ratio for Conmed stock?
The price to earnings (P/E) ratio for Conmed (CNMD) stock is 14.26 as of September 18, 2025.
Does Conmed stock pay dividends?
Yes, the Conmed (CNMD) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $0.8 and the yield is 1.58%. Conmed has a payout ratio of 22.42% on a trailing twelve-month basis.
When is the next Conmed dividend payment date?
The next Conmed (CNMD) dividend payment is scheduled for October 03, 2025.
What is the beta indicator for Conmed?
Conmed (CNMD) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.